CGTLive® Weekly Rewind: Key Advances in Gene and Cell Therapy
- Here are five important updates from this week's coverage of gene and cell therapies.
- Genethon’s Gene Therapy GNT0004 Stabilizes or Improves Motor Functions in Patients With Duchenne Muscular Dystrophy In a recent study, all three patients who received the high dose of...
- Georg Schett discussed early findings from two studies on CD19 CAR T-cell therapy.
CGTLive® Weekly Rewind
Welcome to CGTLive®’s Weekly Rewind! Here are five important updates from this week’s coverage of gene and cell therapies.
-
Genethon’s Gene Therapy GNT0004 Stabilizes or Improves Motor Functions in Patients With Duchenne Muscular Dystrophy
In a recent study, all three patients who received the high dose of GNT0004 showed stabilization of their motor functions. This was measured using the 34-point North Star Ambulatory Assessment.
-
Exploring CAR-T for Autoimmune Disease
Dr. Georg Schett discussed early findings from two studies on CD19 CAR T-cell therapy. He shared insights into its potential for treating autoimmune diseases.
-
FDA Approves StemCyte’s Cord Blood Cell Therapy Regenecyte
The FDA approved Regenecyte for use in unrelated donor hematopoietic progenitor cell transplantation. This decision was based on data from three different studies.
-
Future Trends for Genomic Medicines
David Barrett, CEO of ASGCT, discussed future trends in genomic medicine. His insights were based on the organization’s Q3 Landscape Report.
- Cabaletta Bio’s CAR-T CABA-201 Shows Clinical Responses in Autoimmune Diseases
Patients with lupus, myositis, and systemic sclerosis showed clinical responses to the CAR-T CABA-201 treatment.
Stay tuned for more updates on advancements in the field of gene and cell therapies!